NEW YORK — The best time to treat irregular astigmatism around cataract surgery may be determined by looking at the corneal topography in the pupil zone, according to a speaker here. “Look at the central cornea. If the central cornea is relatively symmetric, then a toric IOL can be reasonable,” Uday Devgan, MD, said at OSN New York 2013.
NEW YORK — UVA and riboflavin cross-linking could be considered for infectious keratitis treatments for better visual outcomes, but more studies are needed, according to a speaker here. Such methods are important to consider because only about half of patients report good visual outcomes when using traditional treatment methods after a corneal infection, Penny A. Asbell, MD, MBA, FACS said at OSN New York 2013. New possibilities also are needed because of increasing multidrug resistance to antibiotics and reduced effectiveness because antibiotic and antifungal agents often do not penetrate tissue (Read more...)
NEW YORK — Photorefractive keratectomy can offer results comparable to LASIK surgery without some of the risks, according to a speaker here.In both the short and long term, photorefractive keratectomy (PRK) outcomes are similar to LASIK while eliminating flap concerns and reducing the likelihood of ectasia, Christopher E. Starr, MD, FACS, said at OSN New York 2013. PRK also now results in less pain than traditionally has been associated with the procedure and is an easier, cheaper and quicker surgery to perform than LASIK.
NEW YORK — Richard L. Lindstrom, MD, discusses his early experience with the Alcon Centurion cataract surgery platform from OSN New York 2013.”I’ve done about 50 cases with it now,” Lindstrom said of the recently announced device. “The active fluidics, … maintaining a more stable chamber, setting whatever you want for IOP is, to me, definitely an advance.”
NEW YORK — Uday Devgan, MD, discusses the importance of adjusting lens calculations in astigmatic cases at OSN New York 2013.Devgan focused on means to more acurately predict the post-operative refraction.
If there is any one condition I dread seeing, it is dermatitis of the eyelids. It is easy to treat with cortisone ointment – unless it comes back. Then what?The condition is a challenge for the dermatologist also.
OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.The A3 adenosine receptor agonist is a novel small molecule, orally bioavailable drug that displayed efficacy and safety during phase 2 clinical studies, according to a press release.
Rigel Pharmaceuticals has announced plans to focus its resources on three lead clinical programs, including a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus.The San Francisco-based company will discontinue development of fostamatinib, an oral SYK inhibitor, for treating rheumatoid arthritis or lymphoma because of insufficient efficacy findings in recent clinical trials, as well as “the competitive landscape for the agent in these indications,” according to a press release.
The Centurion Vision System, a new phacoemulsification platform, will be available this year in nations in which it has received necessary regulatory approvals, Alcon announced in a press release.“By combining multiple proprietary technologies and unique innovations as part of the Centurion Vision System, we are offering surgeons the next-generation phaco platform that will enable them to optimize every step of the cataract surgery,” Stephen Speares, Alcon’s Global Head of Cataract Franchise, said in the release.
ThromboGenics has acquired exclusive rights to develop and commercialize treatments based on Bicycle Therapeutics’ bicyclic peptides that may offer the potential to improve treatment of diabetic macular edema, according to a news release. The companies will work together on preclinical development of the bicyclic peptide inhibitors as part of the collaboration and license agreement, the release said.
The Joint Commission on Allied Health Personnel in Ophthalmology has named Karl Golnik, MD, MEd, to serve as president for the next 2 years, according to a news release.Golnik is a neuro-ophthalmologist at the University of Cincinnati Neuroscience Inst…
In a recent decision, (Township Pharmacy v. Division of Medical Assistance and Health Services) a New Jersey appellate court upheld the denial of a pharmacy owner’s application to participate in the New Jersey Medicaid program as a pharmaceutical service provider because he failed to disclose an employee’s criminal past on his application.Despite the owner’s lack of knowledge of the pharmacy technician’s criminal background when he submitted his application to be a Medicaid provider and his subsequent firing of the employee once he discovered her criminal background, the court sustained the (Read more...)
Epiretinal membrane surgery yielded similar anatomic and visual outcomes and complication rates in highly myopic and non-highly myopic eyes without traction maculopathy, according to a study.The retrospective study included 509 eyes of 509 patients who…
A preservative-free, single-dose formulation of Ganfort ophthalmic solution has been granted marketing authorization covering all 27 European Union countries by the European Medicines Agency, according to a news release.Ganfort (bimatoprost 0.03% / tim…
AcuFocus, maker of the Kamra small-aperture intracorneal inlay, has added Daniel S. Durrie, MD, Richard L. Lindstrom, MD, and John A. Vukich, MD, to its advisory leadership team, according to a company news release.“We look forward to working closely with our vast team … to ensure we meet our internal R&D, commercial, clinical and regulatory objectives,” Jim Mazzo, executive chairman and CEO for AcuFocus, said in the release.
The Drummond Group’s Electronic Health Records Office of the National Coordinator Authorized Certification Body program has cleared Medflow’s EHR v8.1 software, according to a news release.The certification ensures the software is compliant with criteria adopted by the Secretary of the U.S. Department of Health and Human Services, and that users will qualify for stage 1 and 2 meaningful use, the release said.
The U.K.’s National Institute for Health and Care Excellence issued a final appraisal determination for Jetrea confirming the vitreomacular traction treatment option will be recommended for reimbursement in England and Wales via the National Health Service, according to a news release.The final appraisal determination also expanded potential cases in which use of Jetrea (ocriplasmin, ThromboGenics) may be reimbursed to include patients with symptoms of early vitreomacular traction (VMT) such as metamorphopsia, the release said. The treatment is recommended for reimbursement for full-thickness macular hole up to 400 µm in diameter (Read more...)
Nutritional supplements were associated with a reduced risk of progressive neovascular age-related macular degeneration, according to the Age-Related Eye Disease Study; however, the supplements did not reduce the risk of geographic atrophy.AREDS includ…
Reducing preoperative keratometric readings by −1.19 D led to highly predictable postoperative refractive errors after cataract surgery in conjunction with Descemet’s stripping automated endothelial keratoplasty, according to a study.The prospective, interventional case series included 39 patients with Fuchs’ endothelial dystrophy and cataract scheduled for phacoemulsification, IOL implantation and DSAEK.
Single and paired intrastromal corneal ring segments combined with corneal cross-linking improved visual acuity and reduced astigmatism in eyes with keratconus, according to a study.Investigators retrospectively evaluated 85 eyes of 74 patients with ke…